News

Article

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

Author(s):

Fact checked by:

Key Takeaways

  • NT-I7 treatment post-CAR T-cell therapy is safe and enhances efficacy in relapsed/refractory DLBCL patients.
  • The study reported an 81.1% objective response rate, with a 63.6% complete response rate and no severe adverse effects.
SHOW MORE

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Armin Ghobadi, MD

Armin Ghobadi, MD

Treatment with NT-I7 (efineptakin alfa)—a long-acting interleukin 7 (IL-7) agent—was safe and enhanced CAR T factors associated with efficacy for standard-of-care (SOC) CD19-directed CAR T-cell therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to interim results from a phase 1b study (NCT04855283) presented at the 2024 ESMO Congress.1

Findings showed that among patients treated with CAR T-cell therapy followed by 1 of the first 5 dose levels of NT-17 21 days post–CAR T infusion (n =11), the objective response rate (ORR) was 81.1%, including a complete response rate of 63.6% and a partial response rate of 18.2%; the progressive disease rate was 18.2%. The median progression-free survival was 92.0 days, and the median overall survival was 363 days.

Regarding safety, grade 1/2 treatment-emergent adverse effects (TEAEs) related to NT-17 were reported in 54.5% of patients. Notably, no instances of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome occurred after the administration of NT-17.

"Interim data from this ongoing dose-escalation [study] indicates that NT-I7 treatment post–CAR T-[cell therapy] is safe and well tolerated in patients with advanced DLBCL up to 480 µg/kg [dose level 5]. Additionally, NT-I7 successfully enhances all CAR T factors associated with efficacy when administered at day 21 after CAR T infusion,” lead study author Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, Missouri, explained during a presentation of the data.

Study Design and Patient Characteristics

The ongoing, multicenter study is enrolling patients at least 18 years of age with histologically confirmed relapsed/refractory LBCL, including DLBCL not otherwise specified, high grade B-cell lymphoma, DLBCL arising from follicular lymphoma, and primary mediastinal large B-cell lymphoma, who are eligible for SOC CD19-directed CAR T-cell therapy.2 Patients are required to have an ECOG performance status of 0 or 1, a life expectancy of at least 12 weeks, and adequate organ and bone marrow function.

Following screening, eligible patients are receiving SOC CAR T-cell therapy with tisagenlecleucel (Kymriah), lisocabtagene maraleucel (liso-cel; Breyanzi), or axicabtagene ciloleucel (axi-cel; Yescarta) on day 0.1 At day 21, patients are then receiving NT-17 at 60 µg/kg (dose level 1), 120 µg/kg (dose level 2), 240 µg/kg (dose level 3), 360 µg/kg (dose level 4), 480 µg/kg (dose level 5), 600 µg/kg (dose level 6), or 720 µg/kg (dose level 7).Dose levels 1 and 2 were administered to 1 patient each; dose levels 3 to 7 are being administered in a standard 3+3 design.

The study’s primary end points are safety and determining the maximum tolerated dose and/or recommended phase 2 dose of NT-17. Secondary end points including antitumor activity and the effects on NT-17 on CAR T expansion.

As of January 2024, 11 patients were treated at 1 of the first 5 dose levels on NT-17. These patients had a mean age of 66.5 years (range, 49-80). Additionally, 45.5% had stage IV lymphoma at baseline, 36.4% had stage III disease, 9.1% of patients had stage II disease, and stage information was missing for 9.1% of patients.

Furthermore, 45.5% of the patients underwent 4 or more prior treatment regimens; 36.4% had 3 prior lines of therapy, and 18.2% received 2 prior lines of therapy. Most patients (63.6%) had an ECOG performance status of 1 at screening; 27.3% of patients had a performance status of 0, and performance status data were missing for 9.1% of patients.

The majority of patients (n = 9) received tisagenlecleucel. Liso-cel and axi-cel were given to 1 patient each.

Additional Safety and CAR T Data

The most common TEAEs related to NT-17 included injection site erythema and swelling, which were both reported in 18.2% of patients. No grade 3 or higher TEAEs related to NT-17 occurred.

Findings also showed that NT-I7 increased absolute lymphocyte counts, leading to enhanced immune reconstitution. When administered on day 21 following the infusion of CAR T-cell therapy, NT-I7 re-expanded the CAR T-cell population. Although the distribution of CD4 and CD8 CAR T cells did not change, CAR T stemness was increased after the administration of NT-17.

References

  1. Ghobadi A, Budde LE, Stermer K, et al. Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL). Ann Oncol. 2024;35(suppl 2):s599. doi:10.1016/j.annonc.2024.08.857
  2. Relapsed/​refractory large B-cell lymphoma with NT-I7 post-CD19 CAR T-cell therapy. ClinicalTrials.gov. Updated February 22, 2024. Accessed October 7, 2024. https://clinicaltrials.gov/study/NCT05075603
Related Videos
Francine Foss, MD
David C. Fisher, MD
Alex Herrera, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.